Douglas Flora: How AI will play a prominent role in that future

Douglas Flora, Executive Medical Director for Oncology Services at St. Elizabeth Healthcare, shared on LinkedIn:

“I wanted to re-boost this important and thought-provoking Substack piece by Eric Topol on ‘Upending Cancer Screening.’ Here, Dr. Topol challenges the conventional wisdom, advocating for a shift towards more personalized and effective cancer screening strategies. His key message? Relying merely on age cutoffs is not enough; we need to factor in individual risk and genetic profiles. I couldn’t agree more! This approach heralds a new era in cancer care, focusing on personalized screening rather than a blanket approach. The goal is early detection tailored to each person’s unique situation, leading to potentially better outcomes and more efficient care.

A motivating excerpt: “In 2023, more than 600,000 Americans will die of cancer and about 2 million will have a new diagnosis of cancer, many at late stages. We have the desperate need to improve upon these statistics, and, through generative A.I. and biomedical innovation, we now have the tools to achieve this big unmet goal. We have come a long way for understanding a healthy individual’s risk of cancer and interpreting the molecular biologic content of a blood sample. If only we can get smart about using all this information.”

And this is just the beginning! Join Dr. Topol and me tomorrow at 11 am ET to kick off our first global virtual summit on AI in Precision Oncology, where we’ll delve into these topics and more. Be part of this crucial conversation. If you’re interested in the future of oncology, and how AI will play a prominent role in that future, please sign up for this free summit! I’m honored to be amongst a world-class group of oncologists and technologists and would love for you to join us!

REGISTRATION –> click here.

AGENDA –> click here.

Registration is free.”

For details click here.
Source: Douglas Flora/LinkedIn